<DOC>
	<DOCNO>NCT00003899</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining chemotherapy bone marrow peripheral stem cell transplantation may allow doctor give high dos chemotherapy drug kill tumor cell . PURPOSE : Phase I trial study effectiveness melphalan thiotepa plus bone marrow peripheral stem cell transplantation treat patient recurrent refractory solid tumor .</brief_summary>
	<brief_title>Chemotherapy Plus Bone Marrow Peripheral Stem Cell Transplantation Treating Patients With Recurrent Refractory Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose melphalan thiopeta patient recurrent refractory solid tumor . II . Evaluate overall survival response rate patient . OUTLINE : This dose escalation study . Patients receive cyclophosphamide IV 1 hour day 1 paclitaxel IV 4 24 hour day 2 , follow daily filgrastim ( G-CSF ) subcutaneously begin day 3 continue day 7 WBCs great 100,000 cells/mm3 . Peripheral blood stem cell ( PBSC ) autologous bone marrow collect day 5-7 . At 30-50 day follow mobilization , patient receive melphalan IV 15-60 minute day -5 -4 thiotepa IV 2 hour day -3 -2 , follow autologous bone marrow transplantation PBSC infusion day 0 . Sequential dose escalation melphalan follow sequential dose escalation thiotepa . Dose escalation cohort 5 patient continue maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 4 , 3 7 , 4 11 , 5 15 patient experience dose limit toxicity . Patients follow 60 day 12 month . PROJECTED ACCRUAL : A total 40 patient accrue study within 4 year .</detailed_description>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm solid tumor Metastatic disease Recurrent refractory Pleural effusion allow , control Brain metastasis allow , symptom control negative MRI PATIENT CHARACTERISTICS : Age : 18 65 Performance status : Karnofsky 70100 % Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 No uncontrolled bleeding Hepatic : Bilirubin great 2.0 mg/dL SGOT and/or SGPT le 3 time normal Renal : Creatinine great 1.5 mg/dL Cardiovascular : Normal EKG Ejection fraction least 45 % Patients abnormal EKG , history myocardial infarction , unstable angina , congestive heart failure , prior cumulative anthracycline dose least 250 mg/m2 , must leave ventricular ejection fraction perform No congestive heart failure uncontrolled hypertension Pulmonary : DLCO great 60 % No pneumonia No asthma , even control Neurologic : No dementia alter mental status Other : No active infection ( e.g. , peritonitis , wound abscess ) HIV negative No prior cyclophosphamide induced hemorrhagic cystitis No serious concurrent systemic disease ( e.g. , diabetes mellitus , hypothyroidism ) No active malignancy Not pregnant Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent immunotherapy Chemotherapy : No concurrent chemotherapy Endocrine therapy : Concurrent hormonal therapy allow Radiotherapy : No concurrent radiotherapy Surgery : At least 2 week since prior surgery recover</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>